Investors aiming to benefit from large price gains frequently use a method that combines two different analytical schools: fundamental and technical analysis. The aim is to find companies with sound basic business condition and good expansion possibilities, which are also displaying positive price behavior indicating a possible rise. A filter for "Strong Growth Stocks with good Technical Setup Ratings" puts this method into practice. It selects for companies showing solid fundamental expansion, reliable earnings, and financial soundness, while their stock charts indicate technical breakout formations, a pause in price that frequently comes before a new price trend. This pairing indicates a stock might be ready for an upward price change, supported by both its business speed and market forces.
Harmony Biosciences Holdings (NASDAQ:HRMY) offers an interesting example of this method at work. The commercial-stage pharmaceutical company, centered on treatments for rare neurological diseases, displays a profile that matches both the fundamental and technical requirements looked for by this systematic method.
Fundamental Condition: The Driver for Expansion
The base of any expansion investment is the company's financial and operational condition. According to ChartMill's detailed fundamental analysis, HRMY receives an overall score of 8 out of 10, with especially high marks in Growth (9), Valuation (9), Profitability (8), and Health (8). This shows a company that is not only getting bigger quickly but is doing so from a place of financial soundness and at a sensible price.
- Notable Expansion Path: HRMY displays strong expansion measures, which are the central part of the filtering method. Over the last year, Revenue increased by 21.13% and Earnings Per Share (EPS) rose by 50.71%. For the future, analysts predict EPS to increase by an average of 35.10% each year. This steady and forecasted high expansion is exactly what expansion investors look for, as it is the main force behind long-term stock gains.
- High Earnings and Margins: Solid expansion is much more worthwhile when it produces earnings. HRMY performs well here, with a Profit Margin of 22.48% and an Operating Margin of 27.32%, putting it with the leading companies in the pharmaceuticals industry. High margins supply the money required to support more expansion, research, and development without heavy need for outside funding.
- Sound Financial Condition: An expanding company needs a steady base. HRMY's financial condition score of 8 shows a sound balance sheet. Important points feature a very low Debt to Free Cash Flow figure of 0.57, showing it could clear all debt in under a year from its cash flow, and an adequate Current Ratio of 3.75. This financial steadiness lowers risk and gives a cushion against market declines or unplanned difficulties.
- Appealing Price Assessment: Even with its solid expansion and earnings, HRMY seems priced low compared to both its industry and the wider market. With a Price/Earnings (P/E) figure of 11.58 and a forward P/E of 8.72, it costs less than about 90% of similar companies in its industry. This price difference is key for the method, as it indicates the market may not yet be completely valuing the company's expansion possibility, presenting a possible chance for investors.
Technical Formation: The Timing Indicator
While fundamentals show what to buy, technical analysis can give hints on when. ChartMill's technical analysis report for HRMY mentions a Setup Rating of 8, pointing out a positive chart formation.
The report mentions "reduced volatility while prices have been consolidating in the most recent period." This time of consolidation, after a large rise from its 52-week low, often creates a base from which the next part of a trend can start. The stock is now testing an important resistance area between $36.83 and $37.57. A clear move above this area, especially with more trading volume, could signal the restart of the longer-term positive trend and draw more buyer attention. The existence of a clear support area around $35.75-$36.74 gives a sensible level for controlling risk, as a drop below that zone would cancel the positive formation.
Why This Pairing Is Important
The connection between HRMY's fundamental and technical views is what makes it a notable candidate from the perspective of this joined method. The solid expansion, earnings, and financial condition give a believable reason for the stock price to increase over time. At the same time, the technical formation suggests the stock might be finishing a time of pause and could be getting ready for that next rise. One without the other has more risk: solid fundamentals without a technical trigger can create a "value trap," while a technical breakout without fundamental backing can be short-lived and turn down fast.
For investors wanting to examine other companies that fit this strict mix of solid expansion fundamentals and positive technical formations, you can see the full filter rules and view present outcomes here: Strong Growth Stocks with good Technical Setup Ratings.
Disclaimer: This article is for information only and is not financial advice, a suggestion, or an offer or request to buy or sell any securities. The information given on Harmony Biosciences Holdings (HRMY) is from supplied data and should not be the only ground for an investment choice. Investing in stocks includes risk, including the possible loss of the original amount. Always do your own complete research and think about talking with a qualified financial advisor before making any investment choices.